Anika Therapeutics, Inc. (NASDAQ:ANIK)

CAPS Rating: 3 out of 5

The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.

Results 1 - 20 of 37 : 1 2 Next »

Recs

0
Member Avatar 401ktimer1 (51.42) Submitted: 4/3/2014 10:15:05 AM : Outperform Start Price: $40.51 ANIK Score: -0.62

IBD 50 Biotech company with real products and reasonable valuation.

Recs

0
Member Avatar staylo2561 (43.88) Submitted: 3/11/2014 10:37:04 AM : Outperform Start Price: $42.57 ANIK Score: -5.70

The new approved drug is based on HRA, and is a one injection shot to the knee for osteoarthritis. I have taken HRA for years....It is a miracle drug.

Recs

0
Member Avatar TerryFool (22.01) Submitted: 3/1/2014 11:05:20 AM : Outperform Start Price: $38.79 ANIK Score: +1.49

BP $39, long term buy, PEG .88

Recs

2
Member Avatar zzlangerhans (99.74) Submitted: 7/18/2013 1:05:27 PM : Underperform Start Price: $19.95 ANIK Score: -88.19

Anika's share price has nearly quadrupled in the last four years but it's hard for me to see how the numbers justify that kind of a move. Orthovisc revenues seem to be improving but it's hard to tell for sure because of quarterly lumpiness exacerbated by a backlog due to manufacturing problems. Meanwhile, clouds remain on the horizon for Anika. The Monovisc PMA doesn't seem any closer to approval after countless years bogged down in FDA bureaucracy. In May the American Academy of Orthopedic Surgeons issued a strong recommendation against hyaluronic acid injections for knee osteoarthritis based on lack of clinical evidence. Finally, the CEO appears to have been selling stock steadily into the rising share price for several months. I'm definitely throwing myself on top of a rising knife here but at some point enough is enough.

Recs

0
Member Avatar 1badbeerad (45.78) Submitted: 7/17/2013 3:07:58 PM : Outperform Start Price: $19.87 ANIK Score: +89.48

Rocket man

Recs

0
Member Avatar TerryHoodSr (49.13) Submitted: 5/27/2013 3:30:28 PM : Outperform Start Price: $30.90 ANIK Score: +23.48

3 YR EPS growth 39%

Recs

0
Member Avatar chris293 (87.27) Submitted: 4/9/2013 10:41:10 PM : Outperform Start Price: $13.72 ANIK Score: +171.16

Putting skin over metal, wasn't that a movie? Really, skin is the body's biggest organ and the need for this medical product of replacement skin
for injuries from any number of causes is great.

Recs

0
Member Avatar Winnerfrommidlan (53.26) Submitted: 4/15/2012 4:14:17 PM : Outperform Start Price: $16.12 ANIK Score: +111.33

Sales and earnings growth is accelerating.

Recs

3
Member Avatar depletemycapital (< 20) Submitted: 3/9/2012 5:01:14 PM : Outperform Start Price: $11.90 ANIK Score: +198.56

okay 1 year later, now year # 5 of my original purchase of ANIK. I finally believe this company has turned the corner. The beating for the stock not staying above $12 was due to the FDA not wanting to give them quick track approval for Monovisc. This is a single injection viscosupplement. It's alreadry approved & sold widely in Europe.

Now, the FDA has all of a sudden slowed the process down, that's for all companies. But Anik is seeking the help of J&J, whose subsidiary Depuy Mitek markets orthovisc ( 3 injections) to help with FDA approval. But the critical point is that management got rid of all the useless agendas of elevess ( or whatever it's called now) & focused on it's core product. Their market share stands @ 14% & growing. Secondly, the Anika s.r.l, their italian subsidiary has turned the corner & is beginning to contribute, profitably. They had the highest of earnings, revenue, this years, sans shennanigans. We may be looking at a company that hits 75 million + in revenue this year & begin to get noticed by the bigger boys.Chuck royce & associates own this also.

So, though I may not be adding anymore, I'd like to retract my harsher comments from earlier last year. I didn't think management would stop doodling around & simply focus on core growth & the rest would follow. But they got it. They finally got it. I hope they continue. While they work on Monovisc, they are doing clinical studies with cingal, which if it works out will be stellar.

I wasn't expecting cost controls, Ankia s.r.l to work out in such fashion. Suffice to say, doubling your eps, sans shennanigans, is a masterful work. Wow, this company may yet turn into a diamond in the rough that I thought it would be 5 years ago.

Only problem, any delays or notifications of delay from FDA crushes the stock, even though it has absolutely no issue from a revenue/ cash flow/ eps metric. So, i gently recant all the stuff I said earlier. i've convinced myself that Anik is a 20-30 dollar stock 3-5 years from now!!!

Recs

1
Member Avatar acts20 (67.75) Submitted: 9/30/2011 10:11:30 AM : Outperform Start Price: $5.41 ANIK Score: +573.11

Ceo sucks. But at low. Buy out prospect. New products

Recs

1
Member Avatar siri22 (< 20) Submitted: 8/31/2011 5:53:55 PM : Outperform Start Price: $6.00 ANIK Score: +510.34

Ceo sucks.....but low end...good products

Recs

1
Member Avatar tunstavurn (< 20) Submitted: 3/2/2011 5:24:57 PM : Underperform Start Price: $9.19 ANIK Score: -291.86

Pending lawsuit with genzyme.
declining margins
Increased competition

Recs

1
Member Avatar Biotechfreak (< 20) Submitted: 2/24/2011 12:09:17 AM : Outperform Start Price: $8.52 ANIK Score: +324.26

Anika Therapeutics has tremendous upside Potential in the near term .

Anika awaiting 4 FDA approvals in the 1H 2011 .The Biotech Company is profitable and cash flow positive .

Anika is definitely one of the best Pick in the Biotech sector .

Recs

0
Member Avatar gsabc (89.70) Submitted: 6/25/2010 9:09:25 AM : Outperform Start Price: $6.16 ANIK Score: +472.50

Small company with very low price-to-book at the moment, but good products , solid revenue stream and great potential growth.

Recs

0
Member Avatar MAD66 (68.18) Submitted: 6/4/2008 12:57:47 PM : Outperform Start Price: $8.81 ANIK Score: +311.59

Good entry point.

Recs

0
Member Avatar ZoomAddict111 (< 20) Submitted: 5/8/2008 1:03:13 AM : Outperform Start Price: $10.53 ANIK Score: +239.28

Strong pipeline/partnerships/mgt. Beaten down by econ fears. Hold until it outperforms the market by thirty percent or so. PE when added was 20.2

Recs

0
Member Avatar capsterok (71.15) Submitted: 4/21/2008 3:42:40 PM : Outperform Start Price: $9.29 ANIK Score: +283.17

Testing out a portfolio of smallish-cap 5-star stocks found using the CAPS screener. All picks have at least 50 allstars backing them, which should be enough to minimize star rating fluctuations. It's been less than a week, but so far so good!

Recs

0
Member Avatar LetterA (83.28) Submitted: 4/6/2008 2:50:07 AM : Outperform Start Price: $9.82 ANIK Score: +264.71

Testing a portfolio of companies that start with the letter "A".

Recs

0
Member Avatar Killa2dahead (67.08) Submitted: 4/3/2008 3:32:19 AM : Outperform Start Price: $9.29 ANIK Score: +285.85

sounds cool

Recs

0
Member Avatar geostathis (54.40) Submitted: 2/8/2008 4:36:22 PM : Outperform Start Price: $11.31 ANIK Score: +205.55

Extremely low Enterprise value. Growing and accelerating earnings. Unfairly punished

Results 1 - 20 of 37 : 1 2 Next »

Featured Broker Partners


Advertisement